🅿🆁🅴🆂🅴🅽🆃🅰🆃🅸🅾🅽🆂

34th Annual Scientific Meeting 2021 5th Dec 2021
COVID-19 and Liver - What Do We Know After Fighting for Nearly Two Years
  Dr Terry Cheuk-Fung Yip (Hong Kong)

Impact of COVI-19 on Hepatitis Elimination - How Can We Counteract?
Prof Chun-Jen Liu (Taiwan)

MAFLD-associated HCC
Prof Vincent Wong (Hong Kong)

Metabolic Management for MAFLD
Prof Jacob George (Australia)

HBV and Liver Failure
Dr James Fung (Hong Kong)

Hepatitis C and Hepatocellular Carcer: To Treat of Not To Treat
Prof Paul Kwo (USA)

Bi-monthly Scientific Meetings of 2021
ALI with Therapeutic Doses of Acetaminophen
Dr Wing I Cheung

Pulmonary Complications in Chronic Liver Disease
Dr Leung Siu Chung

COVID-19 Vaccine and Liver Disease
Dr Henry Liu

Noninvasive Detection of Clinical Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease
Dr Lau Wun Nam

Caucasian Lean Subjects with NAFLD Share Long-term Prognosis of Non-lean
Dr Lam Wai Hin

Annual Scientific Meeting 2020 (Webinar) 29th Nov 2020
HCC Risk after Functional Cure of HBV
Prof Grace Wong (Hong Kong)

Management of Unresectable HCC
Prof Richard S Finn (USA)

Renaming of NAFLD to Metabolic Associated Fatty Liver Disease (MAFLD)
Prof Vincent Wong (Hong Kong)

Bile Acids in the Pathogenesis and Treatment of NASH
Prof Wah-Kheong Chan (Malaysia)

Viral Hepatitis Elimination by 2030 - Is It Achievable?
Dr Homie Razavi (USA)

Armamentarium for Functional Cure of Chronic Hepatitis B (State Of The Art Lecture)
Prof Man-Fung Yuen (Hong Kong)

International Symposium on Hepatology 2018 - 25th Nov 2018
Challenge of HBV prevention at pregnancy
Prof Teerha Piratvisuth (Thailand)

New Therapies in the Treatment of HBV Infection
Prof Man-Fung Yuen (Hong Kong)

Hepatitis B core-related antigen and hepatocellular carcinoma
Dr Elvis To (Hong Kong)

Manipulating microbiome in cirrhotic patients
Prof Jasmohan Bajaj (USA)

Acute on chronic liver failure - where are we now
Prof Jasmohan Bajaj (USA)

HCC risk prediction - what's new?
Prof Grace Wong (Hong Kong)

Non-invasive Assessment of NAFLD
Prof Quentin Anstee (UK)

How We Treat NASH 5 years from now
Prof Quentin Anstee (UK)

What Are The Remaining Questions in Hepatitis C Management
Prof Teerha Piratvisuth (Thailand)

Impact on Globalisation on HBV and HCV
Prof Ching-Lung Lai (Hong Kong)

Advances in Liver Disease Management & Patient Care for Liver Cirrhosis and Transplant - 7th Sep 2018
What's New in EASL Guidelines for the Management of Decompensated Cirrhosis
Dr James Fung (Hong Kong)
20th Joint Annual Scientific Meeting - 26th Aug 2018
Evolution of Liver Fibrosis in Chronic Hepatitis B
Dr Loey Lung-Yi Mak (Hong Kong)
221st Bi-monthly Scientific Meeting - 17th May 2018
Efficacy of Ledipasdvir and Sofosbuvir Treatment of HCV Infection in Patients Co-infected with HBV  (Journal Review)
Dr Mak Wing-Yan, Joyce (Hong Kong)
Nutrition and Non-alcoholic Fatty Liver Disease (Topic Review)
Dr Carlton Li (Hong Kong)
219th Bi-monthly Scientific Meeting - 18th Jan 2018
The Short-Term Incidence of HCC is not Increase After Hepatitis C Treatment with DAAs (Journal Review)
Dr James Fung (Hong Kong)
A Patient with Impaired Liver Function (Topic Review)
Dr Karen Hin-Kwan Luk (Hong Kong)
International Symposium on Hepatology 2017 - 5th Nov 2017
Fibrosis Regression after HBeAg seroconversion in Chronic Hepatitis B Infection
Dr Loey Lung-Yi Mak (Hong Kong)
HBsAg Seroclearance in NA-treated Patients
Prof Grace Lai-Hung Wong (Hong Kong)
New HBV Biomarkers
Assoc Prof Dan Yock Young (Singapore)
Local HCV Epidemiology and DAA Data
Dr Hui Yee-Tak (Hong Kong)
Management of HCV with Decompensated Cirrhosis
Prof Victor de Ledinghen (France)
HCV: Resistance Associated Substitution and Drug Interactions
Assoc Prof Dan Yock Young (Singapore)
Screening Cardiac Patients for Advanced Liver Disease
Dr Lau Yue Leung, Joulen (Hong Kong)
Updates on Transient Elastography
Prof Victor de Ledinghen (France)
Assessment and Management of Potential Liver Transplant Candidates
Dr James Fung (Hong Kong)
New Treatments for NASH
Prof Vincent Wong (Hong Kong)
New Treatments for Chronic Hepatitis B
Prof Henry LY Chan (Hong Kong)
201st Bi-monthly Scientific Meeting - 19th Mar 2015
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C
Dr Jeffrey Wing-Chee Lai (Hong Kong)
200th Bi-monthly Scientific Meeting - 15th Jan 2015
Significant reduction in ESLD burden through National Viral Hepatitis Therapy Program in Taiwan
Dr Stephen Yau-Man Tung (Hong Kong)
International Symposium on Hepatology 2014 - 16th Nov 2014
Genetic diagnosis of liver diseases
Dr Chloe Mak (Hong Kong)
Chronic hepatitis C infection: getting to cure
Dr Jordan Feld (Canada)
Management of viral hepatitis in patients with renal failure
Prof Chun-jen Liu (Taiwan)
Hepatitis B virus reactivation: a tiger in sheep's clothing
Dr Jordan Feld (Canada)
Cost effectiveness of antiviral treatment
Dr Angeline Lo (Hong Kong)
IgG4-related HBP disease - an update on an emerging condition
Dr George Webster (United Kingdom)
HCC prevention in chronic hepatitis B patients
Prof Vincent Wong (Hong Kong)
Primary sclerosing cholangitis - diagnosis, surveillance and management
Dr George Webster (United Kingdom)
Management of HBV-HCV co-infection
Prof Chun-jen Liu (Taiwan)
State of the art lecture: occult hepatitis B infection: why, who and what to do?
Prof Man-fung Yuen (Hong Kong)
198th Bi-monthly Scientific Meeting - 17th Jul 2014
EASL Meeting Abstract Review
Dr Michael KK Li (Tuen Mun Hospital, Hong Kong)
195th Bi-monthly Scientific Meeting - 16th Jan 2014
A hepatitis B patient with bone pain and muscle weakness
Dr CHIU On Pong (Kwong Wah Hospital, Hong Kong)
International Symposium on Hepatology 2013 - 10th Nov 2013
Which hepatitis C patients with advanced liver disease should be treated NOW with
first generation DAA?
Prof Savino Bruno (AO Fatebenefratelli e Oftalmico, Milano, Italy)
Future Therapies for HCV infection
Prof Savino Bruno (AO Fatebenefratelli e Oftalmico, Milano, Italy)
Updates of hepatitis E in Hong Kong
Dr Chi-Wing Chow (Tseung Kwan O Hospital, Hong Kong)
A personalized approach to chronic hepatitis B therapy
Prof Jia-Horng Kao (National Taiwan University College of Medicine and Hospital)
Treatment of dual HCV/HBV infection and reduction of HCC risk
Prof Jia-Horng Kao (National Taiwan University College of Medicine and Hospital)
HCC prediction in chronic hepatitis B patients on antiviral therapy
Dr Grace Lai-Hung Wong (The Chinese University of Hong Kong, Hong Kong)
193rd Bi-monthy Scientific Meeting - 18th Jul 2013
Effect of Type 2 diabetes on risk for malignancies includes hepatocellular carcinoma
in chronic hepatitis C

Dr Sze Yuen Chun (North District Hospital, Hong Kong)
IgG4 related disease
Dr Angeline Lo (Prince of Wales Hospital, Hong Kong)
192nd Bi-monthly Scientific Meeting - 16th May 2013
Anticholestatic effects of bezafibrate in patients with primary biliary cirhrosis treated with UDCA
Dr Wing-I Cheung (Our Lady of Maryknoll Hospital, Hong Kong)
191st Bi-monthy Scientific Meeting - 21st Mar 2013
Serum hepatitis B surface antigen levels help predict disease progression
in patients with low hepatitis B virus loads

Dr Leung Chi-Man (Pamela Youde Nethersole Eastern Hospital, Hong Kong)
Ascites
Dr Cheung Ka-Shing (Queen Mary Hospital, Hong Kong)
190th Bi-monthy Scientific Meeting - 17th January 2013
The combination of octreotide and midodrine is not superior to albumin
in preventing recurrence of ascites after large-volume paracentesis
Dr Tina Fan (Tseung Kwan O Hospital, Hong Kong)
Non-cirrhotic portal hypertension
Dr Wing-Yan Mak (Queen Elizabeth Hospital, Hong Kong)
International Symposium on Hepatology 2012 - 18th Nov 2012
Occult hepatitis B viral infection (OBI) in patients on chemotherapy
Dr Wing-I Cheung (Our Lady of Maryknoll Hospital, Hong Kong)
Management of decompensated chronic hepatitis B
Dr James Fung (Queen Mary Hospital, Hong Kong)
HCV: Emerging treatments
Dr Robert Gish (UC San Diego)
Point-of-care testing: How do we go about moving viral hepatitis testing forward?
Dr Robert Gish (UC San Diego)
Optimal management of hepatocellular carcinoma
Prof Kwang-Hyub Han (Yonsei University College of Medicine, South Korea)
Practical evaluation and monitoring of patients with chronic hepatitis B
Prof Kwang-Hyub Han (Yonsei University College of Medicine, South Korea)
Role of IL28B and ITPA polymorphisms in different genotypes of HCV
Dr Wai-Kay Seto (The University of Hong Kong)
Genetics of alcoholic liver disease
Prof Felix Stickel (University of Berne, Switzerland)
Update on diagnosis and management of non-alcoholic fatty liver disease
Prof Felix Stickel (University of Berne, Switzerland)
New perspective of antiviral therapy in chronic hepatitis B
Dr Grace Lai-Hung Wong (The Chinese University of Hong Kong)
Impact of fatty liver on viral hepatitis
Prof Vincent Wong (The Chinese University of Hong Kong)



VISITOR NUMBER

Disclaimer

(C) 2012 The Hong Kong Association for the Study of Liver Diseases
Webmaster: Dr James Fung